BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 9184402)

  • 1. Pharmacodynamic and safety results of PEG-Hirudin in healthy volunteers.
    Esslinger HU; Haas S; Maurer R; Lassmann A; Dübbers K; Müller-Peltzer H
    Thromb Haemost; 1997 May; 77(5):911-9. PubMed ID: 9184402
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A recombinant hirudin (IK-HIR02) in healthy volunteers. I. Effects on coagulation parameters and bleeding time.
    Schenk JF; Glusa E; Radziwon P; Butti A; Markwardt F; Breddin HK
    Haemostasis; 1996; 26(3):140-9. PubMed ID: 8738588
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anticoagulant efficacy of PEG-Hirudin in patients on maintenance hemodialysis.
    Pöschel KA; Bucha E; Esslinger HU; Ulbricht K; Nörtersheuser P; Stein G; Nowak G
    Kidney Int; 2004 Feb; 65(2):666-74. PubMed ID: 14717940
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A pilot study of subcutaneous recombinant hirudin (HBW 023) in the treatment of deep vein thrombosis.
    Schiele F; Vuillemenot A; Kramarz P; Kieffer Y; Soria J; Soria C; Camez A; Mirshahi MC; Bassand JP
    Thromb Haemost; 1994 May; 71(5):558-62. PubMed ID: 8091380
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reactivation of coagulation after stopping infusions of recombinant hirudin and unfractionated heparin in unstable angina and myocardial infarction without ST elevation: results of a randomized trial. OASIS Pilot Study Investigators. Organization to Assess Strategies for Ischemic++ Syndromes.
    Flather MD; Weitz JI; Yusuf S; Pogue J; Sussex B; Campeau J; Gill J; Schuld R; Joyner CD; Morris AL; Lai C; Théroux P; Marquis JF; Chan YK; Venkatesh G; Jessel A
    Eur Heart J; 2000 Sep; 21(17):1473-81. PubMed ID: 10952840
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Prevention of thrombosis with subcutaneous recombinant hirudin in heparin-induced thrombocytopenia type II. A pilot study].
    Huhle G; Hoffmann U; Hoffmann I; Harenberg J; Heene DL
    Dtsch Med Wochenschr; 2000 Jun; 125(22):686-91. PubMed ID: 10874895
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Direct thrombin inhibition with Rec-hirudin CGP 39393 as prophylaxis of thromboembolic complications after total hip replacement.
    Eriksson BI; Kälebo P; Ekman S; Lindbratt S; Kerry R; Close P
    Thromb Haemost; 1994 Aug; 72(2):227-31. PubMed ID: 7831657
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of two different doses of hirudin on APTT, determined with eight different reagents.
    Monreal M; Monreal L; Ruiz de Gopegui R; Espada Y; Angles AM; Monasterio J
    Thromb Haemost; 1995 Feb; 73(2):219-22. PubMed ID: 7792733
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Weak allergenicity of recombinant hirudin CGP 39393 (REVASC) in immunocompetent volunteers. The European Hirudin in Thrombosis Group (HIT Group).
    Close P; Bichler J; Kerry R; Ekman S; Bueller HR; Kienast J; Marbet GA; Schramm W; Verstraete M
    Coron Artery Dis; 1994 Nov; 5(11):943-9. PubMed ID: 7719527
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biologic effects of recombinant hirudin (CGP 39393) in human volunteers. European Hirudin in Thrombosis Group.
    Verstraete M; Nurmohamed M; Kienast J; Siebeck M; Silling-Engelhardt G; Büller H; Hoet B; Bichler J; Close P
    J Am Coll Cardiol; 1993 Oct; 22(4):1080-8. PubMed ID: 8409044
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and pharmacodynamics of hirudin in man after single subcutaneous and intravenous bolus administration.
    Bichler J; Fichtl B; Siebeck M; Fritz H
    Arzneimittelforschung; 1988 May; 38(5):704-10. PubMed ID: 3415713
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacodynamics and pharmacokinetics of polyethylene glycol-hirudin in patients with chronic renal failure.
    Pöschel KA; Bucha E; Esslinger HU; Nörtersheuser P; Jansa U; Schindler S; Nowak G; Stein G
    Kidney Int; 2000 Dec; 58(6):2478-84. PubMed ID: 11115081
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The pharmacokinetics and pharmacodynamics of enoxaparin in obese volunteers.
    Sanderink GJ; Le Liboux A; Jariwala N; Harding N; Ozoux ML; Shukla U; Montay G; Boutouyrie B; Miro A
    Clin Pharmacol Ther; 2002 Sep; 72(3):308-18. PubMed ID: 12235452
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of PEG-hirudin in clotting parameters and platelet function and its interaction with aspirin in healthy volunteers.
    Esslinger HU; Köhne S; Radziwon P; Walenga JM; Breddin HK
    Clin Appl Thromb Hemost; 2003 Jan; 9(1):79-88. PubMed ID: 12643328
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The influence of infusions of 1-desamino-8-D-arginine vasopressin (DDAVP) in vivo on the anticoagulant effect of recombinant hirudin (CGP39393) in vitro.
    Ibbotson SH; Grant PJ; Kerry R; Findlay VS; Prentice CR
    Thromb Haemost; 1991 Jan; 65(1):64-6. PubMed ID: 1902596
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The inhibitory effect of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, compared with enoxaparin and r-hirudin on ex vivo thrombin generation in human plasma.
    Boström SL; Hansson GF; Sarich TC; Wolzt M
    Thromb Res; 2004; 113(1):85-91. PubMed ID: 15081569
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Markers of hemostatic system activation during thromboprophylaxis with recombinant hirudin in total hip replacement.
    Cofrancesco E; Cortellaro M; Leonardi P; Corradi A; Ravasi F; Bertocchi F
    Thromb Haemost; 1996 Mar; 75(3):407-11. PubMed ID: 8701398
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and anticoagulant effect of hirudin in man.
    Markwardt F; Nowak G; Stürzebecher J; Griessbach U; Walsmann P; Vogel G
    Thromb Haemost; 1984 Oct; 52(2):160-3. PubMed ID: 6523433
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of anticoagulation with subcutaneously delivered polyethylene glycol conjugated hirudin and recombinant tissue plasminogen activator on recurrent stenosis in the rabbit double-balloon injury model.
    Alexander B; Burnand KG; Lattimer CL; Humphries J; Gaffney PJ; Eastham D; Smith A
    Thromb Res; 2004; 113(2):155-61. PubMed ID: 15115671
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ecarin clotting time but not aPTT correlates with PEG-hirudin plasma activity.
    Moser M; Ruef J; Peter K; Kohler B; Gulba DC; Paterna N; Nordt T; Kübler W; Bode C
    J Thromb Thrombolysis; 2001 Oct; 12(2):165-9. PubMed ID: 11729368
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.